The increase in TRAIL-mediated lysis of enzalutamide-treated cells compared to vehicle-treated cells was very similar to that observed when CEA-specific CTLs were used, suggesting that enzalutamide treatment may be specifically affecting the tumor cell's sensitivity to TRAIL-mediated immune cell-induced lysis. Here, CEACAM5 is linked to neoplasm.